Skip to main content

Table 2 Toxicokinetic parameters of Gensci059 in cynomolgus monkeys following multiple-dose administration

From: Gentulizumab, a novel anti-CD47 antibody with potent antitumor activity and demonstrates a favorable safety profile

 

1st dose

2nd dose

4th dose

 

Cmax (mg/mL)

AUClast (h·mg/mL)

AUCinf (h·mg/mL)

Cmax (mg/mL)

AUClast (h·mg/mL)

AUCinf (h·mg/mL)

Cmax (mg/mL)

AUClast (h·mg/mL)

AUCinf (h·mg/mL)

AF (AUC4th/2nd)

Low dose

0.19 ± 0.01

3.1 ± 0.48

3.1 ± 0.48

0.73 ± 0.08

27.33 ± 2.88

28.53 ± 2.94

0.77 ± 0.31

34.12 ± 21.36

36.34 ± 22.96

1.25

Middle dose

0.19 ± 0.04

3.11 ± 0.54

3.11 ± 0.54

2.46 ± 0.23

149.24 ± 22.96

173.14 ± 28.15

2.92 ± 0.32

155 ± 61.03

234.92 ± 132.32

1.04

High dose

0.21 ± 0.02

3.51 ± 0.58

3.51 ± 0.58

8.89 ± 0.71

521.26 ± 60.07

737.03 ± 174.88

7.98 ± 1.31

556.2 ± 178.94

1001.69 ± 503.81

1.07

  1. Cmax maximum observed concentration; AUC Area under the concentration–time curve; AUClast AUC to the Last Measurable Concentration; AUCinf AUC from time 0 to infinity; AF Accumulation factor